House Democratic leadership released H.R. 3, the Lower Drug Costs Now Act of 2019, on September 19, 2019. While the bill was improved from what reports earlier in the summer suggested, there are still numerous provisions of the bill that should be strengthened before it reaches the floor.
However, House leadership plans to move the bill through all three committees of jurisdiction before the end of October, leaving us with only a few legislative days to make an impact in the amendment process. Click here to learn more about key provisions of the bill that should be improved before it reaches the floor of the House of Representatives at the end of the month.
Call Rep. Delado and tell him: improve H.R. 3 by negotiating more drugs, and protecting patients from high launch prices and price spikes!
Hi! My name is <NAME>, and I’m calling from <TOWN> in NY19.
I’m calling to urge Rep. Delgado to support improving H.R. 3 by negotiating more drugs, and protecting patients from high launch prices and price spikes.
H.R. 3 is a good start, but there are key gaps that need to be filled before the House votes on it. Members should support amendments that would increase the number of drugs that are eligible for negotiation and increase the number of drugs that are negotiated each year. They should also improve the bill by protecting all patients from high launch prices and price spikes — two problems that aren’t fixed by negotiating the price of existing drugs alone.
Will Rep. Delgado commit to improving H.R. 3?